Synopsis
Synopsis
0
JDMF
0
VMF
0
Australia
Annual Reports
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Antaxone
2. Celupan
3. En 1639a
4. En-1639a
5. En1639a
6. Nalorex
7. Naltrexone
8. Nemexin
9. Revia
10. Trexan
1. Naltrexone Hcl
2. 16676-29-2
3. Trexan
4. Depade
5. Antaxone
6. Revia
7. Naltrexone (hydrochloride)
8. En-1639a
9. Nih 8503
10. Celupan
11. Nemexin
12. N-cyclopropylmethyl-noroxymorphone Hydrochloride
13. Mls000069607
14. Naltrexone Hydrochloride [usp]
15. Z6375yw9sf
16. Vivitrex
17. 17-(cyclopropylmethyl)-4,5-alpha-epoxy-3,14-dihydroxy-morphinan-6-one Hydrochloride
18. Nalorex
19. Smr000058767
20. En-1639a (as Hydrochloride)
21. En 1639a
22. (4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one;hydrochloride
23. Naltrexone Hydrochloride (usp)
24. (4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,3,4,4a,5,6-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinolin-7(7ah)-one Hydrochloride
25. Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, Hydrochloride (1:1), (5alpha)-
26. Ccris 1168
27. Einecs 240-723-0
28. Unii-z6375yw9sf
29. Naltrel
30. Naltrexone.hcl
31. Naltrexone Depot
32. Prestwick_348
33. Mfcd00069324
34. (5alpha)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one Hydrochloride
35. Revia (tn)
36. Xr-ntx
37. (4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;hydrochloride
38. Opera_id_1828
39. Naltrexone Monohydrochloride
40. Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-alpha-epoxy-3,14-dihydroxy-, Hydrochloride
41. Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, Hydrochloride, (5-alpha)-
42. Schembl37713
43. Mls001076516
44. Mls002153483
45. Mls002695940
46. Cyto-205
47. Chembl1201149
48. Dtxsid50937236
49. Pti-901
50. Chebi:134687
51. Bcp08343
52. Naltrexone Hydrochloride [mi]
53. S2103
54. Vp-004
55. Akos015994597
56. Ccg-268383
57. Cs-0763
58. Hs-0003
59. Nc00693
60. 17-cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one Hydrochloride
61. Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-alpha-oxy-3,14-dihydoxy-, Hydrochloride
62. Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, Hydrochloride, (5alpha)-
63. Naltrexone Hydrochloride [mart.]
64. Naltrexone Hydrochloride [vandf]
65. Naltrexone Hydrochloride [who-dd]
66. Bn164635
67. Hy-76710
68. Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, Hydrochloride, (5.alpha.)-
69. N1176
70. Naltrexone Hydrochloride [green Book]
71. Sw196619-3
72. Naltrexone Hydrochloride [orange Book]
73. D02095
74. Embeda Component Naltrexone Hydrochloride
75. H10489
76. Naltrexone Hydrochloride [ep Monograph]
77. Naltrexone Hydrochloride [usp Monograph]
78. Troxyca Component Naltrexone Hydrochloride
79. 676n292
80. Contrave Component Naltrexone Hydrochloride
81. Naltrexone Hydrochloride Component Of Embeda
82. Naltrexone Hydrochloride Component Of Troxyca
83. Naltrexone Hydrochloride Component Of Contrave
84. Q27096434
85. Z1558290144
86. Naltrexone Hydrochloride 1.0 Mg/ml In Methanol (as Free Base)
87. Naltrexone Hydrochloride, European Pharmacopoeia (ep) Reference Standard
88. (5a)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-morphinan-6-one Hydrochloride
89. 17-(cyclopropylmethyl)-3,14-dihydroxy-4,5alpha-epoxymorphinan-6-one Hydrochloride
90. 17-cyclopropylmethyl)-4,5.alpha.-epoxy-3,14-dihydroxymorphinan-6-one Hydrochloride
91. (1s,5r,13r,17s)-4-(cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-trien-14-one Hydrochloride
92. (4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one;hydron;chloride
93. (5alpha,17r)-17-(cyclopropylmethyl)-3,14-dihydroxy-6-oxo-4,5-epoxymorphinan-17-ium Chloride
94. Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5.alpha.)-, Hydrochloride (1:1)
Molecular Weight | 377.9 g/mol |
---|---|
Molecular Formula | C20H24ClNO4 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 2 |
Exact Mass | 377.1393859 g/mol |
Monoisotopic Mass | 377.1393859 g/mol |
Topological Polar Surface Area | 70 Ų |
Heavy Atom Count | 26 |
Formal Charge | 0 |
Complexity | 621 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 6 | |
---|---|
Drug Name | Naltrexone hydrochloride |
PubMed Health | Naltrexone |
Drug Classes | Ethanol Dependency, Opioid Dependency, Toxicology-Antidote Agent |
Drug Label | Naltrexone hydrochloride, an opioid antagonist, is a synthetic congener of oxymorphone with no opioid agonist properties. Naltrexone differs in structure from oxymorphone in that the methyl group on the nitrogen atom is replaced by a cyclopropylmethy... |
Active Ingredient | Naltrexone hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 25mg; 100mg; 50mg |
Market Status | Prescription |
Company | Accord Hlthcare; Mallinckrodt; Sun Pharma Global; Elite Labs; Barr |
2 of 6 | |
---|---|
Drug Name | Revia |
PubMed Health | Naltrexone |
Drug Classes | Ethanol Dependency, Opioid Dependency, Toxicology-Antidote Agent |
Drug Label | REVIA (naltrexone hydrochloride tablets USP), an opioid antagonist, is a synthetic congener of oxymorphone with no opioid agonist properties. Naltrexone differs in structure from oxymorphone in that the methyl group on the nitrogen atom is replaced... |
Active Ingredient | Naltrexone hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 50mg |
Market Status | Prescription |
Company | Teva Womens |
3 of 6 | |
---|---|
Drug Name | Vivitrol |
Active Ingredient | Naltrexone |
Dosage Form | For suspension, extended release |
Route | Intramuscular |
Strength | 380mg/vial |
Market Status | Prescription |
Company | Alkermes |
4 of 6 | |
---|---|
Drug Name | Naltrexone hydrochloride |
PubMed Health | Naltrexone |
Drug Classes | Ethanol Dependency, Opioid Dependency, Toxicology-Antidote Agent |
Drug Label | Naltrexone hydrochloride, an opioid antagonist, is a synthetic congener of oxymorphone with no opioid agonist properties. Naltrexone differs in structure from oxymorphone in that the methyl group on the nitrogen atom is replaced by a cyclopropylmethy... |
Active Ingredient | Naltrexone hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 25mg; 100mg; 50mg |
Market Status | Prescription |
Company | Accord Hlthcare; Mallinckrodt; Sun Pharma Global; Elite Labs; Barr |
5 of 6 | |
---|---|
Drug Name | Revia |
PubMed Health | Naltrexone |
Drug Classes | Ethanol Dependency, Opioid Dependency, Toxicology-Antidote Agent |
Drug Label | REVIA (naltrexone hydrochloride tablets USP), an opioid antagonist, is a synthetic congener of oxymorphone with no opioid agonist properties. Naltrexone differs in structure from oxymorphone in that the methyl group on the nitrogen atom is replaced... |
Active Ingredient | Naltrexone hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 50mg |
Market Status | Prescription |
Company | Teva Womens |
6 of 6 | |
---|---|
Drug Name | Vivitrol |
Active Ingredient | Naltrexone |
Dosage Form | For suspension, extended release |
Route | Intramuscular |
Strength | 380mg/vial |
Market Status | Prescription |
Company | Alkermes |
Alcohol Deterrents
Substances interfering with the metabolism of ethyl alcohol, causing unpleasant side effects thought to discourage the drinking of alcoholic beverages. Alcohol deterrents are used in the treatment of alcoholism. (See all compounds classified as Alcohol Deterrents.)
Narcotic Antagonists
Agents inhibiting the effect of narcotics on the central nervous system. (See all compounds classified as Narcotic Antagonists.)
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Faran Shimi: Leading producer of high-quality APIs & alkaloid opiates, serving major pharmaceutical companies across the Middle East.
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-03-17
Pay. Date : 2013-03-11
DMF Number : 20623
Submission : 2007-06-20
Status : Active
Type : II
Certificate Number : CEP 2009-287 - Rev 03
Issue Date : 2024-03-01
Type : Chemical
Substance Number : 1790
Status : Valid
Registrant Name : Samoh Pharmaceutical Co., Ltd.
Registration Date : 2019-05-30
Registration Number : 20190530-209-J-359
Manufacturer Name : Sanofi Winthrop Industrie
Manufacturer Address : Route d'Avignon 30390 Aramon, France
Available Reg Filing : CN |
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
NDC Package Code : 50396-6008
Start Marketing Date : 2013-12-05
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Product Not Available For Sales
GDUFA
DMF Review : Reviewed
Rev. Date : 2015-06-16
Pay. Date : 2012-12-20
DMF Number : 15102
Submission : 2000-10-18
Status : Active
Type : II
NDC Package Code : 60870-0395
Start Marketing Date : 1990-01-30
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
Certificate Number : R1-CEP 2016-053 - Rev 00
Issue Date : 2023-01-13
Type : Chemical
Substance Number : 1790
Status : Valid
Date of Issue : 2025-02-11
Valid Till : 2027-06-09
Written Confirmation Number : WC-0278
Address of the Firm :
NDC Package Code : 70312-0887
Start Marketing Date : 2015-12-16
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING
Registrant Name : Phamchem Service Co., Ltd.
Registration Date : 2023-10-16
Registration Number : 20210611-209-J-542(2)
Manufacturer Name : Rusan Pharma Ltd.
Manufacturer Address : Plot no. 6406, GIDC ESTATE, ANKLESHWAR, City : ANKLESHWAR - 393 002, Dist : Bharuch, Gujarat State, India
Deccan Nutraceuticals: A global leader in the integrated development, manufacturing, and marketing of pharmaceutical products.
NDC Package Code : 45085-0292
Start Marketing Date : 2024-08-26
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
11
PharmaCompass offers a list of Naltrexone Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Naltrexone Hydrochloride manufacturer or Naltrexone Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Naltrexone Hydrochloride manufacturer or Naltrexone Hydrochloride supplier.
PharmaCompass also assists you with knowing the Naltrexone Hydrochloride API Price utilized in the formulation of products. Naltrexone Hydrochloride API Price is not always fixed or binding as the Naltrexone Hydrochloride Price is obtained through a variety of data sources. The Naltrexone Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A ReVia manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of ReVia, including repackagers and relabelers. The FDA regulates ReVia manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. ReVia API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of ReVia manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A ReVia supplier is an individual or a company that provides ReVia active pharmaceutical ingredient (API) or ReVia finished formulations upon request. The ReVia suppliers may include ReVia API manufacturers, exporters, distributors and traders.
click here to find a list of ReVia suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A ReVia DMF (Drug Master File) is a document detailing the whole manufacturing process of ReVia active pharmaceutical ingredient (API) in detail. Different forms of ReVia DMFs exist exist since differing nations have different regulations, such as ReVia USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A ReVia DMF submitted to regulatory agencies in the US is known as a USDMF. ReVia USDMF includes data on ReVia's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The ReVia USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of ReVia suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a ReVia Drug Master File in Korea (ReVia KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of ReVia. The MFDS reviews the ReVia KDMF as part of the drug registration process and uses the information provided in the ReVia KDMF to evaluate the safety and efficacy of the drug.
After submitting a ReVia KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their ReVia API can apply through the Korea Drug Master File (KDMF).
click here to find a list of ReVia suppliers with KDMF on PharmaCompass.
A ReVia CEP of the European Pharmacopoeia monograph is often referred to as a ReVia Certificate of Suitability (COS). The purpose of a ReVia CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of ReVia EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of ReVia to their clients by showing that a ReVia CEP has been issued for it. The manufacturer submits a ReVia CEP (COS) as part of the market authorization procedure, and it takes on the role of a ReVia CEP holder for the record. Additionally, the data presented in the ReVia CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the ReVia DMF.
A ReVia CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. ReVia CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of ReVia suppliers with CEP (COS) on PharmaCompass.
A ReVia written confirmation (ReVia WC) is an official document issued by a regulatory agency to a ReVia manufacturer, verifying that the manufacturing facility of a ReVia active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting ReVia APIs or ReVia finished pharmaceutical products to another nation, regulatory agencies frequently require a ReVia WC (written confirmation) as part of the regulatory process.
click here to find a list of ReVia suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing ReVia as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for ReVia API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture ReVia as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain ReVia and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a ReVia NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of ReVia suppliers with NDC on PharmaCompass.
ReVia Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of ReVia GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right ReVia GMP manufacturer or ReVia GMP API supplier for your needs.
A ReVia CoA (Certificate of Analysis) is a formal document that attests to ReVia's compliance with ReVia specifications and serves as a tool for batch-level quality control.
ReVia CoA mostly includes findings from lab analyses of a specific batch. For each ReVia CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
ReVia may be tested according to a variety of international standards, such as European Pharmacopoeia (ReVia EP), ReVia JP (Japanese Pharmacopeia) and the US Pharmacopoeia (ReVia USP).